Bachem AG is a leading global CDMO specializing in the development and manufacture of peptides and oligonucleotides, with over 50 years of experience. Headquartered in Bubendorf, Switzerland, Bachem provides end-to-end services from research-grade synthesis and CMC development through GMP-scale commercial API manufacturing for pharmaceutical and biotechnology companies worldwide. The company leverages innovative technologies including Multi-Column Solvent Gradient Purification (MCSGP) for higher throughput and purity. Bachem holds a strong regulatory track record and a partnership with Eli Lilly for oligonucleotide-based drug substance development and manufacturing (since April 2022). They serve the peptide therapeutics market including GLP-1 receptor agonists and other complex peptide APIs.
peptide synthesis and manufacturing, oligonucleotide manufacturing, MCSGP purification technology, CMC development, complex peptide APIs, GMP peptide production
3 sites worldwide
No reviews available yet.
No documents available.